2024
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
Ebrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, Bergerot C, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu S, Chehrazi-Raffle A, Vaishampayan U, Staehler M, Pal S. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients 2024, 16: 1630. PMID: 38892563, PMCID: PMC11174627, DOI: 10.3390/nu16111630.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaDietary modificationSupplement useDiagnosis of renal cell carcinomaFirst-line treatmentSupplement usageSystemic therapyCombination therapyAntineoplastic therapyKetogenic dietCarcinomaCancer therapyMediterranean dietPhysician-patient dialoguePatientsTherapyCancer treatmentGrowing body of evidenceBody of evidenceDietary changesCancerCancer diagnosisCannabidiolImpact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).
Mercier B, Tripathi N, Govindarajan A, Gebrael G, Narang A, Li X, Castro D, Chehrazi-Raffle A, Dizman N, Ebrahimi H, Chawla N, Hsu J, Bergerot C, Barragan-Carrillo R, Zengin Z, Meza L, Pal S, Agarwal N, Tripathi A. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2024, 42: 547-547. DOI: 10.1200/jco.2024.42.4_suppl.547.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaOverall survivalCox proportional hazards multivariate modelPresence of visceral metastasesChi-square test/Fisher's exact testIS groupPractice patternsPredictors of OSKaplan-Meier methodImpact practice patternsLog-rank testMedicare groupPrivate insuranceMulti-institutional studyANOVA/Kruskal-Wallis testVisceral metastasesInsurance payer statusNeoadjuvant chemotherapyNCI-designated comprehensive cancer centerSystemic therapyUrothelial carcinomaMedian ageBaseline characteristicsExact testClinical trial participationOutcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Lemelin A, Ernst M, Wells J, Saliby R, El Zarif T, Labaki C, Basappa N, Szabados B, Powles T, Davis I, Wood L, Lalani A, McKay R, Lee J, Meza L, Pal S, Donskov F, Yuasa T, Beuselinck B, Gebrael G, Agarwal N, Choueiri T, Heng D. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology 2024 PMID: 38290965, DOI: 10.1016/j.eururo.2024.01.006.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumBrain metastasesRenal cell carcinomaStereotactic radiotherapyOverall survivalSystemic therapyCell carcinomaAssociated with longer median overall survivalAssociated with longer overall survivalInitiation of systemic therapyLonger median overall survivalAssociated with longer OSTyrosine kinase inhibitor monotherapyAssociated with better prognosisIO-based regimensMedian overall survivalWhole-brain radiotherapyFirst-line therapyAdvanced kidney cancerLonger overall survivalOutcomes of patientsGroup of patientsCombination immunotherapyLonger OSInhibitor monotherapy
2023
Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab
Tripathi N, Meza L, Sayegh N, Govindarajan A, Byron S, Zhang J, Chigarira B, Jo Y, Zengin Z, Li H, Gebrael G, Desai A, Agarwal N, Swami U, Maughan B, Pal S. Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab. Kidney Cancer 2023, 7: 137-145. DOI: 10.3233/kca-230011.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaClear cell metastatic renal cell carcinomaClinical benefit groupRenal cell carcinomaClinical benefitNivolumab therapyCell carcinomaPoor-risk metastatic renal cell carcinomaMetastatic clear cell renal cell carcinomaBenefit groupClear cell renal cell carcinomaFirst-line ipilimumabIMDC risk scoresFirst-line treatmentCell renal cell carcinomaAlteration frequencyChi-square testMRCC patientsStable diseaseComplete responsePartial responseSystemic therapyLine treatmentInflammatory pathwaysTumor-specific gene expressionAssessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
Castro D, Prajapati S, Feng M, Chan E, Lee K, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Ebrahimi H, Govindarajan A, Meza L, Mercier B, Chawla N, Dizman N, Philip E, Hsu J, Bergerot C, Chehrazi‐Raffle A, Rock A, Liu S, Tripathi A, Dorff T, Pal S. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy. BJU International 2023, 133: 297-304. PMID: 37548533, DOI: 10.1111/bju.16148.Peer-Reviewed Original ResearchHBV/HCV infectionExclusion of patientsHepatitis B virusConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionSystemic therapyRCC trialsVirus infectionExact testHepatitis C virus infectionHuman immunodeficiency virus (HIV) infectionC virus infectionImmunodeficiency virus infectionFisher's exact testRestrictive eligibility criteriaContext of HIVChi-square testPrevalent comorbiditiesHIV infectionImmunotherapy trialsPatient populationB virusTrial characteristicsThe impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
Castro D, Tripathi N, Sayegh N, Gebrael G, Li X, Meza L, Zengin Z, Chehrazi-Raffle A, Govindarajan A, Dizman N, Ebrahimi H, Chawla N, Mercier B, BS J, Shi J, Philip E, Bergerot C, Barragan-Carrillo R, Pal S. The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). The Oncologist 2023, 28: s5-s6. PMCID: PMC10445577, DOI: 10.1093/oncolo/oyad216.008.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMedian progression-free survivalProgression-free survivalLog-rank testMedian overall survivalOverall survivalMedicaid/Insurance statusSecondary insurancePrivate insurancePrimary insuranceSystemic therapyClinical outcomesEntire cohortInferior median progression-free survivalSuperior median progression-free survivalSignificant differencesCox proportional hazards regression modelFirst-line systemic therapyMedicaid/uninsured patientsSuperior progression-free survivalProportional hazards regression modelsLine systemic therapyFirst-line treatmentKaplan-Meier methodPrevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).
Ebrahimi H, Battle D, Zengin Z, Dizman N, Meza L, Castro D, Govindarajan A, Mercier B, Chawla N, Chehrazi-Raffle A, Tripathi A, Liu S, Vaishampayan U, Staehler M, Pal S. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 662-662. DOI: 10.1200/jco.2023.41.6_suppl.662.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaDietary modificationSupplement useCell carcinomaSupplement intakeKetogenic dietSupplement usageActive systemic therapyNivolumab/ipilimumabFirst-line treatmentMajority of patientsT-testPatient advocacy groupsChi-square testStudent's t-testClinical trial candidatesOnly patientsSystemic therapyMedian ageAntineoplastic treatmentProspective studyPotential confoundersInclusion criteriaMediterranean diet
2022
How to Treat Renal Cell Carcinoma The Current Treatment Landscape and Cardiovascular Toxicities
Castro D, Malhotra J, Meza L, Govindarajan A, Philip E, Pal S. How to Treat Renal Cell Carcinoma The Current Treatment Landscape and Cardiovascular Toxicities. JACC CardioOncology 2022, 4: 271-275. PMID: 35818545, PMCID: PMC9270613, DOI: 10.1016/j.jaccao.2022.04.004.Peer-Reviewed Original ResearchTranscriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).
Zengin Z, Govindarajan A, Muddasani R, Salgia N, Sayegh N, Tripathi N, Salgia S, Meza L, Zhang J, Chawla N, Chehrazi-Raffle A, Malhotra J, Dizman N, Hsu J, Castro D, Byron S, Dandapani S, Pal S. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 4555-4555. DOI: 10.1200/jco.2022.40.16_suppl.4555.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaStereotactic body radiation therapySystemic treatmentSystemic therapyLess benefitCompletion of SBRTRole of SBRTHigh expressionBody radiation therapyRenal cell carcinomaT-testStudent's t-testHypoxia-related genesCommon histologyOligoprogressive diseaseClinicopathologic characteristicsMedian ageFischer's exactClinical benefitCell carcinomaClear cellsRadiation therapyTreatment durationTreatment changesIncreased expressionProlonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.
Muddasani R, Govindarajan A, Salgia S, Salgia N, Zengin Z, Meza L, Hsu J, Chehrazi-Raffle A, Dizman N, Chawla N, Malhotra J, Bergerot C, Philip E, Castro D, Dandapani S, Tripathi N, Sayegh N, Pal S. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy. Journal Of Clinical Oncology 2022, 40: 336-336. DOI: 10.1200/jco.2022.40.6_suppl.336.Peer-Reviewed Original ResearchSystemic therapyNational Comprehensive Cancer Network guidelinesMetastatic renal cell carcinomaStereotactic body radiation therapyMedian total doseClear cell histologyFirst-line therapyFrequent side effectsLines of therapyPreponderance of patientsRetrospective data collectionBody radiation therapyRenal cell carcinomaEfficacy of radiotherapyMRCC patientsMedian doseCell histologyNew regimensSystemic treatmentClinicopathologic characteristicsRT toxicityClinical benefitNetwork guidelinesSame therapyCell carcinoma
2021
Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal S. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal For ImmunoTherapy Of Cancer 2021, 9: e002009. PMID: 33688021, PMCID: PMC7944971, DOI: 10.1136/jitc-2020-002009.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaRenal cell carcinomaImmune checkpoint inhibitorsColony-stimulating factorClinical benefitPlasma cytokinesSystemic therapyCell carcinomaInterleukin-6Prospective correlative studyLines of therapyLow pretreatment levelsGranulocyte colony-stimulating factorGranulocyte-macrophage colony-stimulating factorRCC histologic subtypesMacrophage colony-stimulating factorICI armsICI therapyStable diseaseCheckpoint inhibitorsClinical responsePartial responseComplete responseImmunologic profileDistinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC).
Chehrazi-Raffle A, Meza L, Alcantara M, Salgia N, Dizman N, Bergerot P, Hsu J, Kortylewski M, Pal S. Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 352-352. DOI: 10.1200/jco.2021.39.6_suppl.352.Peer-Reviewed Original ResearchVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaImmune checkpoint inhibitorsPlasma cytokinesClinical benefitCommon immune checkpoint inhibitorsICI combination therapyLow pretreatment levelsRenal cell carcinomaEligible patientsICI armsStable diseaseCheckpoint inhibitorsImmunologic profilePartial responseSystemic therapyComplete responseProspective studyIL-1raCell carcinomaCombination therapyIL-6Pretreatment levelsDistinct cytokinesG-CSF